Analysis of clinicopathological features, treatment modalities, and survival outcomes in advanced gastric and colorectal signet ring cell carcinoma Authors: Jie Xu, Luojie Liu, Zhaoji Zhu Published: 2025 ABSTRACT AbstractBackgroundAdvanced gastric and colorectal signet ring cell carcinoma (SRCC) exhibit distinct biological behaviors, yet comprehensive characterization of their clinicopathological features, treatment modalities, and survival disparities remains limited. Leveraging the Surveillance, Epidemiology, and End Results (SEER) database, this population-based study aimed to elucidate these critical aspects.MethodsWe retrospectively analyzed 15,214 patients with American Joint Committee on Cancer (AJCC) stage III/IV gastric (n = 10,203) or colorectal (n = 5011) SRCC diagnosed between 2000 and 2021. Clinicopathological characteristics and survival outcomes were compared across cohorts. Four treatment modalities were evaluated: surgery alone, chemotherapy (CT) alone, surgery + CT, and no therapy. Kaplan–Meier analysis and Cox proportional hazards regression were used to assess overall survival (OS) and cancer-specific survival (CSS).ResultsDeclining incidence trends were observed for both malignancies. CT alone was the most frequent treatment in gastric SRCC (39.3%), whereas surgery + CT predominated in colorectal SRCC (47.5%). Colorectal SRCC demonstrated significantly superior OS (HR: 0.62, 95% CI: 0.60–0.65, P < 0.001) and CSS (HR: 0.62, 95% CI: 0.60–0.65, P < 0.001) compared to gastric SRCC across all stratified subgroups. The 5-year OS/CSS rates were 6.3%/7.7% for gastric vs. 18.2%/23.0% for colorectal SRCC. Surgery + CT was associated with improved OS and CSS in both gastric and colorectal cohorts, regardless of AJCC stage III/IV. Multivariate analysis identified age, primary site, stage, treatment, and marital status as independent prognosticators.ConclusionsThis study highlights significant clinicopathological and prognostic heterogeneity between advanced gastric and colorectal SRCC, with colorectal tumors demonstrating more favorable outcomes. Surgery + CT may improve survival, highlighting the need for personalized treatment strategies based on the primary tumor site.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-025-04263-8.Keywords: Advanced signet ring cell carcinoma, Gastric and colorectal cancer, Clinicopathological characteristics, Treatment modalities, Survival outcomes Introduction Signet ring cell carcinoma (SRCC) is a rare but highly aggressive histological subtype characterized by intracellular mucin accumulation that displaces the nucleus, yielding a classic “signet ring” morphology [1, 2]. Although SRCC can arise in various organs, the stomach and colorectum are the most common primary sites, with gastric SRCC and colorectal SRCC demonstrating distinct biological behaviors and clinical courses [3–5]. Despite progress in diagnostic imaging and systemic therapies, advanced-stage SRCC continues to portend a poor prognosis [6–8], underscoring the need for a more profound understanding of its clinicopathological heterogeneity and optimal management strategies. Previous research has largely centered on gastric SRCC, linking it to a younger age at onset, diffuse infiltration patterns, and a propensity for peritoneal dissemination, all of which contribute to its notably dismal survival rates [9–14]. For example, Xu et al. [9] developed a prognostic nomogram for gastric SRCC based on lymph node involvement, emphasizing the pivotal role of nodal metastasis in stratifying survival. Similarly, Jiang et al. [10] introduced a dynamic web-based nomogram that integrates clinicopathological and immune factors to predict outcomes in gastric SRCC. Collectively, these studies highlight the biological complexity of gastric SRCC and the necessity for personalized prognostic tools. In contrast, comprehensive analyses of colorectal SRCC remain limited, and direct comparative studies of gastric versus colorectal SRCC in large cohorts, particularly focusing on advanced-stage disease, are entirely lacking. Emerging evidence indicates that colorectal SRCC possesses unique clinical characteristics, such as higher rates of lymphovascular invasion and distant metastasis compared to conventional colorectal adenocarcinoma [15–17]. Preliminary findings also suggest differences in treatment responsiveness, although these observations are constrained by the rarity of colorectal SRCC and associated diagnostic difficulties [18, 19]. Crucially, no population-level study has yet systematically delineated the survival disparities, treatment patterns, or clinicopathological distinctions between advanced gastric SRCC and colorectal SRCC, resulting in a significant gap in evidence-based clinical management. To address this critical knowledge gap, we leveraged the Surveillance, Epidemiology, and End Results (SEER) database—a high-quality, population-based registry encompassing approximately 30% of the U.S. population—to perform the first comprehensive comparative analysis of advanced gastric and colorectal SRCC. By directly comparing these two malignancies, we aimed to elucidate their divergent biological and clinical profiles, with the goal of informing standardized treatment guidelines and improving patient outcomes. This study was designed to clarify differences in survival, therapeutic response, and pathological features between these SRCC subtypes, thereby contributing to the advancement of precision oncology strategies. Materials and methods Patient selection This investigation included patients diagnosed with gastric and colorectal SRCC between 2000 and 2021, leveraging data extracted from the SEER registry. Case identification was performed using ICD-O-3 (International Classification of Diseases for Oncology, 3rd Edition) morphology code 8490/3 specific to SRCC. Patients were excluded if definitive histopathological confirmation was absent, survival data were incomplete, or American Joint Committee on Cancer (AJCC) staging was classified as I, II, or unknown. A schematic overview of the study cohort selection process is provided in Fig. 1. Comprehensive analyses were conducted across multiple clinical dimensions, including patient age, sex, racial/ethnic background, primary tumor site, histologic differentiation, AJCC stage, surgical intervention status, chemotherapy (CT) exposure, marital status, overall survival (OS), cancer-specific survival (CSS), and duration of follow-up. Age stratification was optimized via X-tile software (Supplementary Fig. 1), establishing two cohorts: <75 years and ≥ 75 years. Racial/ethnic categories comprised white, black, or other (encompassing American Indian/Alaska Native and Asian/Pacific Islander). The analytic sample was restricted to patients with AJCC stage III or IV malignancies, defined per the 8th Edition AJCC Staging Manual as “T4M0 with any N category” for stage III and “M1 with any T/N combination” for stage IV [20]. Marital status was dichotomized into married and unmarried groups, with the latter category aggregating divorced/separated, never married, and widowed individuals. The primary objectives were to characterize clinicopathological profiles, therapeutic approaches, and long-term oncologic outcomes in gastric and colorectal SRCC. Survival endpoints (OS and CSS) were measured from the date of SRCC diagnosis to the earliest event of all-cause mortality, cancer-related death, or censoring at last follow-up. Given the de-identified nature of SEER data, Institutional Review Board (IRB) approval and informed consent requirements were waived for this retrospective analysis. Patient selection flowchart. The diagram illustrates the identification and inclusion process of patients with advanced gastric and colorectal signet ring cell carcinoma (SRCC) from the SEER database (2000–2021), detailing the exclusion criteria applied to form the final study cohort Statistical analysis Categorical variables were presented as frequencies and percentages, with group comparisons performed using chi-square tests. For continuous variables that deviated from a normal distribution, medians and interquartile ranges (IQRs) were utilized, and the Mann-Whitney U test was applied for comparative analysis. To address missing data in the SEER database, an advanced approach integrating multiple imputation (MI) with the random forest algorithm was implemented. Survival analysis was conducted using the Kaplan-Meier method, with log-rank tests employed to compare survival curves. Univariate and multivariate Cox proportional hazards regression models were developed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Variables demonstrating statistical significance (P < 0.05) in univariate analysis were incorporated into the multivariate Cox regression model. All statistical analyses were carried out using R software (version 4.1.0), with a significance threshold of P < 0.05. Results Patients characteristics A total of 15,214 patients were enrolled, comprising 10,203 with gastric SRCC and 5011 with colorectal SRCC. The majority of patients (77.7%) were aged < 75 years, with a slight male predominance (52.1% vs. 47.9%). Poorly differentiated tumors accounted for the vast majority of cases (89.6%). Gastric SRCC patients exhibited a significantly higher proportion of AJCC stage IV disease compared to colorectal SRCC counterparts (72.0% vs. 48.0%, P < 0.001). Surgical intervention was administered to nearly half of the cohort (50.2%), while 63.0% received CT. Clinicopathological characteristics of gastric and colorectal SRCC patients are summarized in Table 1. Supplementary Table 1 details the pre-imputation clinicopathological profiles, noting missing data rates: race (0.4%), tumor grade (18.1%), surgical procedure (0.2%), and marital status (3.8%). Table 1Comparison of the demographic and clinical characteristics of patients with gastric and colorectal SRCCVariablesTotal (n = 15,214)Stomach group (n = 10,203)Colorectum group (n = 5011)P-valueAge, years, n (%)< 0.001 < 7511,816 (77.7%)8303 (81.4%)3513 (70.1%) ≥ 753398 (22.3%)1900 (18.6%)1498 (29.9%)Sex, n (%) < 0.001 Male7926 (52.1%)5216 (51.1%)2710 (54.1%) Female7288 (47.9%)4987 (48.9%)2301 (45.9%)Race, n (%) < 0.001 White11,555 (75.9%)7399 (72.5%)4156 (82.9%) Black1574 (10.3%)1113 (10.9%)461 (9.2%) Others2085 (13.7%)1691 (16.6%)394 (7.9%)Grade, n (%) < 0.001 Well113 (0.7%)61 (0.6%)52 (1.0%) Moderately563 (3.7%)216 (2.1%)347 (6.9%) Poorly13,639 (89.6%)9711 (95.2%)3928 (78.4%) Undifferentiated899 (5.9%)215 (2.1%)684 (13.6%)AJCC stage, n (%) < 0.001 III5462 (35.9%)2854 (28.0%)2608 (52.0%) IV9752 (64.1%)7349 (72.0%)2403 (48.0%)Surgery, n (%) < 0.001 Yes7634 (50.2%)3690 (36.2%)3944 (78.7%) No7580 (49.8%)6513 (63.8%)1067 (21.3%)Chemotherapy, n (%) < 0.001 Yes9578 (63.0%)6588 (64.6%)2990 (59.7%) No/Unknown5636 (37.0%)3615 (35.4%)2021 (40.3%)Marital status, n (%) < 0.001 Married8921 (58.6%)6205 (60.8%)2716 (54.2%) Unmarried6293 (41.4%)3998 (39.2%)2295 (45.8%)Survival months, median (IQR)8.0 (3.0, 19.0)7.0 (2.0, 15.0)13.0 (4.0, 31.0) < 0.001 SRCC signet ring cell carcinoma, Others American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, IQR interquartile range, bold values indicate P < 0.05 Comparison of the demographic and clinical characteristics of patients with gastric and colorectal SRCC SRCC signet ring cell carcinoma, Others American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, IQR interquartile range, bold values indicate P < 0.05 Survival analysis of patients with gastric and colorectal SRCC The 5-year OS rate for gastric SRCC was 6.3%, with a corresponding CSS rate of 7.7%. For AJCC stage III gastric SRCC patients, the 5-year OS rate was 16.3% and the CSS rate was 19.0%. In AJCC stage IV gastric SRCC cases, the 5-year OS rate dropped to 2.3%, with a CSS rate of 2.9%. Colorectal SRCC patients showed a 5-year OS rate of 18.2%, accompanied by a CSS rate of 23.0%. Among AJCC stage III colorectal SRCC patients, the 5-year OS rate reached 32.0%, while the CSS rate was 40.0%. For AJCC stage IV colorectal SRCC patients, the 5-year OS rate was 3.1%, with a CSS rate of 4.1%. Table 2 provides detailed 1-, 3-, 5-, and 10-year OS and CSS rates for both gastric and colorectal SRCC cohorts. Figure 2 illustrates the Kaplan-Meier curves for OS and CSS in gastric and colorectal SRCC patients. Compared to gastric SRCC, colorectal SRCC exhibited significantly improved OS (HR: 0.62, 95% CI: 0.60–0.65, P < 0.001) (Fig. 2A) and CSS (HR: 0.62, 95% CI: 0.60–0.65, P < 0.001) (Fig. 2B). Subgroup analyses stratified by age, sex, race, tumor grade, AJCC stage, surgical intervention, CT status, and marital status consistently demonstrated superior OS (Fig. 3A) and CSS (Fig. 3B) in colorectal SRCC patients across all strata. Table 2Survival analysis of gastric and colorectal SRCCNumber at riskNumber of eventsSurvival (%)95%CI Lower95%CI UpperOS rate of gastric SRCC 1-year3443650134.233.335.2 3-year881216110.29.610.9 5-year4483066.35.86.9 10-year1541344.03.64.5OS rate of AJCC stage III gastric SRCC 1-year1709108660.959.162.7 3-year60396123.922.325.6 5-year33617516.314.917.8 10-year11010310.18.911.5OS rate of AJCC stage IV gastric SRCC 1-year1734541523.622.724.7 3-year27812004.74.25.3 5-year1121312.31.92.7 10-year44311.51.21.9OS rate of colorectal SRCC 1-year2667229453.452.054.8 3-year1123131924.923.726.2 5-year72728018.217.119.4 10-year33823811.510.612.6OS rate of AJCC stage III colorectal SRCC 1-year181175170.668.972.4 3-year97170741.339.443.3 5-year66720332.030.133.9 10-year31721120.618.922.4OS rate of AJCC stage IV colorectal SRCC 1-year856154334.832.936.8 3-year1526127.06.08.1 5-year60773.12.54.0 10-year21271.71.22.3CSS rate of gastric SRCC 1-year3443612236.435.437.4 3-year881204311.711.012.4 5-year4482727.77.18.3 10-year154915.75.26.3CSS rate of AJCC stage III gastric SRCC 1-year170999063.661.865.4 3-year60390126.624.928.4 5-year33615419.017.420.7 10-year1106814.112.615.8CSS rate of AJCC stage IV gastric SRCC 1-year1734513225.424.426.5 3-year27811425.55.06.2 5-year1121182.92.53.4 10-year44232.21.82.6CSS rate of colorectal SRCC 1-year2667202357.556.158.9 3-year1123119429.027.630.4 5-year72721023.021.724.3 10-year33812918.217.019.5CSS rate of AJCC stage III colorectal SRCC 1-year181159775.774.177.5 3-year97161047.845.849.9 5-year66714440.037.942.1 10-year31710732.430.334.6CSS rate of AJCC stage IV colorectal SRCC 1-year856142637.635.639.6 3-year1525848.27.09.5 5-year60664.13.35.2 10-year21222.51.83.4SRCC signet ring cell carcinoma, OS overall survival, CSS cancer specific survival, AJCC American Joint Committee on Cancer, CI confidence interval Survival analysis of gastric and colorectal SRCC SRCC signet ring cell carcinoma, OS overall survival, CSS cancer specific survival, AJCC American Joint Committee on Cancer, CI confidence interval Comparative survival analysis between gastric and colorectal SRCC. Kaplan-Meier curves demonstrate significantly superior A overall survival (OS) and B cancer-specific survival (CSS) for patients with colorectal SRCC compared to those with gastric SRCC (both P < 0.001) Subgroup analyses of survival outcomes. Forest plots show hazard ratios (HRs) with 95% confidence intervals for A overall survival (OS) and B cancer-specific survival (CSS), comparing colorectal SRCC to gastric SRCC across various patient and tumor characteristics. The colorectal SRCC group consistently exhibits a survival advantage in all predefined subgroups Univariate and multivariate Cox regression Univariate Cox regression analysis identified age, race, primary tumor location, tumor grade, AJCC stage, treatment modality, and marital status as significant predictors of OS in patients with gastric and colorectal SRCC. Multivariate analysis confirmed the independence of these associations, retaining age, race, primary tumor location, AJCC stage, treatment modality, and marital status as prognostic factors for OS (Table 3). Similarly, for CSS, univariate models highlighted the same covariates, while multivariate analysis demonstrated that age, primary tumor location, AJCC stage, treatment modality, and marital status were independent predictors of CSS (Table 4). Table 3Univariate and multivariate Cox regression for analyzing the overall survival for patients with gastric and colorectal SRCCVariablesUnivariateMultivariateHR95% CIP-valueHR95% CIP-valueAge, years < 751.00Reference1.00Reference ≥ 751.361.30, 1.41 < 0.001 1.261.21, 1.31 < 0.001 Sex Male1.00Reference––– Female0.970.94, 1.010.139–––Race White1.00Reference1.00Reference Black1.101.04, 1.17 < 0.001 1.071.01, 1.13 0.016 Others0.960.91, 1.010.1010.930.88, 0.97 0.003 Primary site Stomach1.00Reference1.00Reference Colorectum0.620.60, 0.65 < 0.001 0.820.79, 0.86 < 0.001 Grade Well1.00Reference1.00Reference Moderately0.880.71, 1.090.2260.900.72, 1.110.312 Poorly1.080.88, 1.310.4631.020.84, 1.250.806 Undifferentiated0.810.66, 0.99 0.042 1.080.87, 1.330.489AJCC stage III1.00Reference1.00Reference IV2.762.66, 2.87 < 0.001 1.991.90, 2.08 < 0.001 Treatment No therapy1.00Reference1.00Reference Surgery only0.240.23, 0.26 < 0.001 0.370.35, 0.40 < 0.001 Chemotherapy only0.330.31, 0.34 < 0.001 0.340.33, 0.36 < 0.001 Surgery + Chemotherapy0.130.12, 0.13 < 0.001 0.200.19, 0.22 < 0.001 Marital status Married1.00Reference1.00Reference Unmarried1.181.14, 1.22 < 0.001 1.111.07, 1.15 < 0.001 SRCC signet ring cell carcinoma, HR hazard ratios, CI confidence interval, Others: American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, bold values indicate P < 0.05 Univariate and multivariate Cox regression for analyzing the overall survival for patients with gastric and colorectal SRCC SRCC signet ring cell carcinoma, HR hazard ratios, CI confidence interval, Others: American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, bold values indicate P < 0.05 Table 4Univariate and multivariate Cox regression for analyzing the cancer-specific survival for patients with gastric and colorectal SRCCVariablesUnivariateMultivariateHR95% CIP-valueHR95% CIP-valueAge, years < 751.00Reference1.00Reference ≥ 751.211.16, 1.27 < 0.001 1.161.11, 1.21 < 0.001 Sex Male1.00Reference––– Female0.970.94, 1.010.094–––Race White1.00Reference1.00Reference Black1.101.03, 1.16 0.002 1.050.99, 1.110.114 Others0.990.94, 1.050.8320.950.90, 1.000.056Primary site Stomach1.00Reference1.00Reference Colorectum0.580.55, 0.60 < 0.001 0.780.75, 0.82 < 0.001 Grade Well1.00Reference1.00Reference Moderately0.850.68, 1.060.1590.890.71, 1.110.300 Poorly1.040.85, 1.270.7230.990.81, 1.210.902Undifferentiated0.740.60, 0.92 0.007 1.040.84, 1.290.730AJCC stage III1.00Reference1.00Reference IV3.022.90, 3.15 < 0.001 2.132.03, 2.24 < 0.001 Treatment No therapy1.00Reference1.00Reference Surgery only0.220.21, 0.23 < 0.001 0.360.34, 0.39 < 0.001 Chemotherapy only0.340.32, 0.35 < 0.001 0.350.33, 0.36 < 0.001 Surgery + Chemotherapy0.130.12, 0.13 < 0.001 0.210.20, 0.22 < 0.001 Marital status Married1.00Reference1.00Reference Unmarried1.151.11, 1.20 < 0.001 1.101.06, 1.14 < 0.001 SRCC signet ring cell carcinoma, HR hazard ratios, CI confidence interval, Others: American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, bold values indicate P < 0.05 Univariate and multivariate Cox regression for analyzing the cancer-specific survival for patients with gastric and colorectal SRCC SRCC signet ring cell carcinoma, HR hazard ratios, CI confidence interval, Others: American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, bold values indicate P < 0.05 In gastric SRCC patients, univariate analysis revealed age, race, tumor grade, AJCC stage, treatment modality, and marital status as significant predictors of OS. Multivariate Cox regression confirmed the independent prognostic value of age, race, AJCC stage, treatment modality, and marital status for OS (Supplementary Table 2). For CSS, univariate predictors mirrored OS findings, with multivariate analysis retaining age, race, AJCC stage, treatment modality, and marital status as independent predictors (Supplementary Table 3). For colorectal SRCC patients, univariate models identified age, sex, tumor grade, AJCC stage, treatment modality, and marital status as significant predictors of OS. Multivariate analysis further established age, sex, AJCC stage, treatment modality, and marital status as independent prognostic factors for OS (Supplementary Table 4). CSS analysis yielded comparable results, with univariate predictors including age, sex, tumor grade, AJCC stage, treatment modality, and marital status, and multivariate models confirming the independence of age, sex, AJCC stage, treatment modality, and marital status (Supplementary Table 5). Survival analysis of different treatment methods for patients with gastric and colorectal SRCC In this study, there were four treatment modalities for gastric and colorectal SRCC: surgery alone, CT alone, surgery + CT, and no therapy. Table 5 details the clinicopathological characteristics of gastric SRCC patients across the four treatment groups. Table 6 provides analogous clinicopathological features for colorectal SRCC patients stratified by the four treatment modalities. Figure 6B shows that surgery + CT was the predominant treatment for colorectal SRCC, followed by surgery alone. Supplementary Tables 6 and 7 illustrate temporal changes in the number and proportion of the four treatment modalities for gastric and colorectal cancers, respectively. Table 5Demographic and clinical characteristics of patients with gastric SRCC stratified by treatment modalitiesVariablesTreatment modalitiesP-valueNo therapy (n = 2506)Surgery only (n = 1109)Chemotherapy only (n = 4007)Surgery + Chemotherapy (n = 2581)Age, years, n (%)< 0.001 < 751741 (69.5%)697 (62.8%)3554 (88.7%)2311 (89.5%) ≥ 75765 (30.5%)412 (37.2%)453 (11.3%)270 (10.5%)Sex, n (%)0.238 Male1284 (51.2%)540 (48.7%)2041 (50.9%)1351 (52.3%) Female1222 (48.8%)569 (51.3%)1966 (49.1%)1230 (47.7%)Race, n (%) < 0.001 White1833 (73.1%)771 (69.5%)2993 (74.7%)1802 (69.8%) Black302 (12.1%)123 (11.1%)403 (10.1%)285 (11.0%) Others371 (14.8%)215 (19.4%)611 (15.2%)494 (19.1%)Grade, n (%) < 0.001 Well50 (2.0%)3 (0.3%)6 (0.1%)2 (0.1%) Moderately91 (3.6%)20 (1.8%)64 (1.6%)41 (1.6%) Poorly2324 (92.7%)1045 (94.2%)3889 (97.1%)2453 (95.0%) Undifferentiated41 (1.6%)41 (3.7%)48 (1.2%)85 (3.3%)AJCC stage, n (%) < 0.001 III157 (6.3%)585 (52.8%)405 (10.1%)1707 (66.1%) IV2349 (93.7%)524 (47.2%)3602 (89.9%)874 (33.9%)Marital status, n (%) < 0.001 Married1275 (50.9%)616 (55.5%)2521 (62.9%)1793 (69.5%) Unmarried1231 (49.1%)493 (44.5%)1486 (37.1%)788 (30.5%)Survival months, median (IQR)1.0 (0, 3.0)6.0 (2.0, 16.0)7.0 (4.0, 13.0)17.0 (9.0, 34.0) < 0.001 SRCC signet ring cell carcinoma, Others: American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, IQR interquartile range; bold values indicate P < 0.05 Demographic and clinical characteristics of patients with gastric SRCC stratified by treatment modalities SRCC signet ring cell carcinoma, Others: American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, IQR interquartile range; bold values indicate P < 0.05 Table 6Demographic and clinical characteristics of patients with colorectal SRCC stratified by treatment modalitiesVariablesTreatment modalitiesP-valueNo therapy (n = 456)Surgery only (n = 1565)Chemotherapy only (n = 611)Surgery + Chemotherapy (n = 2379)Age, years, n (%)< 0.001 < 75263 (57.7%)766 (48.9%)527 (86.3%)1957 (82.3%) ≥ 75193 (42.3%)799 (51.1%)84 (13.7%)422 (17.7%)Sex, n (%) < 0.001 Male268 (58.8%)761 (48.6%)402 (65.8%)1279 (53.8%) Female188 (41.2%)804 (51.4%)209 (34.2%)1100 (46.2%)Race, n (%)0.063 White374 (82.0%)1336 (85.4%)495 (81.0%)1951 (82.0%) Black47 (10.3%)131 (8.4%)60 (9.8%)223 (9.4%) Others35 (7.7%)98 (6.3%)56 (9.2%)205 (8.6%)Grade, n (%) < 0.001 Well3 (0.7%)15 (1.0%)0 (0.0%)34 (1.4%) Moderately43 (9.4%)88 (5.6%)66 (10.8%)150 (6.3%) Poorly390 (85.5%)1218 (77.8%)533 (87.2%)1787 (75.1%) Undifferentiated20 (4.4%)244 (15.6%)12 (2.0%)408 (17.2%)AJCC stage, n (%) < 0.001 III28 (6.1%)1000 (63.9%)47 (7.7%)1533 (64.4%) IV428 (93.9%)565 (36.1%)564 (92.3%)846 (35.6%)Marital status, n (%) < 0.001 Married226 (49.6%)732 (46.8%)348 (57.0%)1410 (59.3%) Unmarried230 (50.4%)833 (53.2%)263 (43.0%)969 (40.7%)Survival months, median (IQR)1.0 (0, 3.0)7.0 (2.0, 26.0)9.0 (5.0, 16.0)21.0 (11.0, 48.0) < 0.001 SRCC signet ring cell carcinoma, Others: American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, IQR interquartile range; bold values indicate P < 0.05 Demographic and clinical characteristics of patients with colorectal SRCC stratified by treatment modalities SRCC signet ring cell carcinoma, Others: American Indian, Alaska Native, Asian/Pacifc Islander, AJCC American Joint Committee on Cancer, IQR interquartile range; bold values indicate P < 0.05 For gastric SRCC patients, compared to the no therapy group, the surgery + CT group demonstrated the most favorable OS (HR: 0.13, 95% CI: 0.12–0.14, P < 0.001) (Fig. 4A) and CSS (HR: 0.13, 95% CI: 0.12–0.14, P < 0.001) (Fig. 4B). Among AJCC stage III gastric SRCC patients, the surgery + CT group also exhibited superior OS (HR: 0.13, 95% CI: 0.11–0.16, P < 0.001) (Fig. 4C) and CSS (HR: 0.13, 95% CI: 0.11–0.16, P < 0.001) (Fig. 4D) relative to no therapy. Similarly, for AJCC stage IV gastric SRCC patients, the surgery + CT group showed improved OS (HR: 0.19, 95% CI: 0.17–0.20, P < 0.001) (Fig. 4E) and CSS (HR: 0.19, 95% CI: 0.18–0.21, P < 0.001) (Fig. 4F) compared to no therapy. Impact of treatment modalities on survival in gastric SRCC. Kaplan–Meier curves depict (A, C, E) overall survival (OS) and (B, D, F) cancer-specific survival (CSS) for gastric SRCC patients stratified by four treatment strategies: no therapy, chemotherapy alone, surgery alone, and surgery plus chemotherapy. Analyses are presented for the entire advanced cohort (A, B), patients with AJCC stage III disease (C, D), and patients with AJCC stage IV disease (E, F). The combination of surgery plus chemotherapy was associated with the most favorable outcomes across all stages In colorectal SRCC patients, the surgery + CT group likewise demonstrated the best OS (HR: 0.14, 95% CI: 0.13–0.16, P < 0.001) (Fig. 5A) and CSS (HR: 0.14, 95% CI: 0.13–0.16, P < 0.001) (Fig. 5B) versus no therapy. For AJCC stage III colorectal SRCC patients, the surgery + CT group exhibited significantly better OS (HR: 0.30, 95% CI: 0.20–0.45, P < 0.001) (Fig. 5C) and CSS (HR: 0.33, 95% CI: 0.21–0.52, P < 0.001) (Fig. 5D) compared to no therapy. Similarly, among AJCC stage IV colorectal SRCC patients, the surgery + CT group showed enhanced OS (HR: 0.21, 95% CI: 0.19–0.24, P < 0.001) (Fig. 5E) and CSS (HR: 0.22, 95% CI: 0.19–0.25, P < 0.001) (Fig. 5F) relative to no therapy. Impact of treatment modalities on survival in colorectal SRCC. Kaplan–Meier curves depict (A, C, E) overall survival (OS) and (B, D, F) cancer-specific survival (CSS) for colorectal SRCC patients stratified by four treatment strategies: no therapy, chemotherapy alone, surgery alone, and surgery plus chemotherapy. Analyses are presented for the entire advanced cohort (A, B), patients with AJCC stage III disease (C, D), and patients with AJCC stage IV disease (E, F). The combination of surgery plus chemotherapy was consistently associated with the best survival outcomes Discussion Despite an overall decline in gastric cancer incidence, the annual incidence of gastric SRCC continues to rise [12, 21–23]. Comprising 35–45% of all gastric cancer cases [21], gastric SRCC frequently presents with aggressive pathological features that often lead to diagnosis at an advanced stage [13, 24]. Notably, our study reveals a decreasing trend in the annual incidence of advanced gastric SRCC, a finding mirrored in advanced colorectal SRCC patients. This observation may be attributed to advancements in endoscopic technologies, including magnifying endoscopy with narrow-band imaging (ME-NBI) and endoscopic ultrasound (EUS), alongside optimized screening protocols that have improved early detection rates [25, 26]. Additionally, therapeutic breakthroughs in immunotherapy and targeted therapies, along with the implementation of Helicobacter pylori infection prevention and eradication strategies, have contributed to reduced disease progression and carcinogenesis risk [27]. Previous studies have established that early-stage gastric SRCC is associated with favorable prognoses, surpassing other gastric cancer subtypes with a 5-year survival rate exceeding 80% [24, 28]. In contrast, early-stage colorectal SRCC demonstrates a significantly poorer prognosis, with a 5-year survival rate below 30% [29]. While the prognosis of early gastric SRCC is distinctly superior to colorectal SRCC, no prior investigations have directly compared advanced-stage disease. Our study addresses this gap, revealing that among advanced SRCC patients, colorectal SRCC is associated with a more favorable prognosis than gastric SRCC. This may be attributed to the increased metastatic potential, elevated lymph node metastasis rates, and propensity for peritoneal dissemination in advanced gastric SRCC, collectively complicating treatment strategies [24]. The intricate anatomy of the stomach also poses challenges to achieving radical surgical resection. In our cohort, only 36.2% of gastric SRCC patients underwent surgical intervention, compared to 78.7% of colorectal SRCC patients. Furthermore, gastric SRCC may display reduced sensitivity to conventional CT regimens, and therapeutic options including targeted and immunotherapy remain limited, further impacting clinical outcomes. Multivariate Cox regression analysis confirmed tumor location as an independent prognostic factor, with colorectal SRCC demonstrating a survival advantage over gastric SRCC. It is well-documented in existing research that age acts as a significant prognostic indicator for SRCC patients, with younger age groups frequently exhibiting worse clinical outcomes than older patients [30–32]. However, our present investigation uncovers a contrasting trend in advanced SRCC patients, wherein elderly patients (≥ 75 years) exhibit worse prognoses than their non-elderly counterparts (Tables 3 and 4). This observed disparity in the advanced-disease setting can be ascribed to several clinically relevant factors. First, elderly patients frequently present with a higher burden of comorbidities and diminished physiological reserve, which often restricts their eligibility for and tolerance of intensive multimodal therapies, such as radical surgery or combination CT. This can lead to treatment de-escalation, early discontinuation, or even exclusion from potentially curative-intent regimens, ultimately compromising oncologic outcomes. Second, age-related immunosenescence—the progressive decline in immune function—may impair antitumor immune surveillance and the capacity to eradicate residual cancer cells, thereby accelerating disease progression. Furthermore, diagnostic delays are more common in the elderly, who may attribute symptoms to benign conditions or face barriers in accessing timely healthcare, leading to diagnosis at a more advanced and less treatable disease stage. Consequently, while young SRCC patients generally face poorer prognoses across all stages, our findings highlight that in the specific context of advanced SRCC, elderly patients experience significantly worse outcomes, underscoring the critical need for tailored management strategies that carefully balance treatment efficacy with tolerability in this vulnerable population. Our study identified several critical determinants of prognosis in advanced SRCC. Consistent with our findings, Yan et al. [33] also reported tumor location as a significant risk factor. Treatment modality represents another pivotal factor, with patients undergoing surgery, CT, or combined therapies exhibiting significantly improved prognoses relative to untreated patients [16, 30, 31, 34]. Specifically, Li et al. [35] demonstrated that CT enhances the prognosis of stage II–III primary gastric SRCC patients. Our investigation reveals that combined surgery and CT yields the most favorable outcomes for advanced gastric and colorectal SRCC patients, irrespective of stage III or IV disease. This integrated approach enables comprehensive tumor control by excising macroscopic lesions while systemically targeting micrometastases, thereby mitigating recurrence risks. The synergy between surgery and CT may further augment antitumor efficacy through enhanced tumor cell susceptibility and postoperative microenvironment alterations. Furthermore, the choice of CT regimen may also influence outcomes in advanced SRCC. A recent multicenter retrospective study from Turkey compared the efficacy of mFOLFOX-6 and mDCF regimens in metastatic gastric cancer, demonstrating comparable survival benefits between the two regimens, though with distinct toxicity profiles [36]. This finding underscores the importance of regimen selection and personalized treatment planning in metastatic gastric cancer, including SRCC, and aligns with our observation that systemic therapy—particularly when combined with surgery—confers a significant survival advantage. Additionally, marital status was identified as a significant prognostic factor, with unmarried patients demonstrating poorer outcomes across various malignancies, including SRCC [37–40]. Potential mechanisms may include enhanced emotional and financial support facilitating earlier diagnosis and treatment adherence, improved compliance with therapeutic regimens, and psychological benefits that indirectly improve immune function and therapeutic efficacy in married patients. The superior prognosis of colorectal SRCC may stem from distinct biological mechanisms. First, metastatic patterns differ critically: gastric SRCC favors peritoneal dissemination, which is surgically challenging and morbid, while colorectal SRCC often spreads hematogenously to the liver/lungs, sites more amenable to local therapies [6, 13, 16, 17]. Second, the tumor microenvironment (TME) varies: gastric SRCC exhibits a profoundly immunosuppressive TME, potentially conferring resistance [1, 2], whereas the colorectal SRCC TME might be less hostile. Third, therapeutic feasibility differs: achieving complete surgical resection is often more feasible for colorectal tumors and their metastases than for diffusely infiltrating gastric cancers with peritoneal involvement [24, 34]. Finally, intrinsic factors such as differential chemosensitivity and molecular landscapes may also contribute [7, 18]. Collectively, these mechanistic differences—in dissemination, TME, and treatment accessibility—provide a plausible rationale for the observed survival gap. Our findings on the differential survival and treatment responses between gastric and colorectal SRCC are further illuminated by recent investigations into the histological and molecular heterogeneity of these tumors. Sorrenti et al. [41] emphasized that neoadjuvant CT significantly improves survival in locally advanced gastric SRCC, reinforcing our observation that multimodal therapy incorporating CT is central to optimizing outcomes. Moreover, the work of Marano et al. [42] and Roviello et al. [43] highlights that the proportion of signet ring cells within a tumor—not merely their presence—carries prognostic significance. In mixed-type gastric cancers, a higher percentage of signet ring cells has been inversely correlated with aggressive behavior, suggesting that histological subtyping and quantitation could refine risk stratification and treatment personalization [42]. This is consistent with our results, wherein tumor origin and subtype distinctly influenced survival. Additionally, Marano et al. [44] recently illustrated that proximal and distal gastric cancers are driven by different molecular master regulators, underscoring the need for site-specific management strategies even within gastric SRCC. Together, these studies provide a mechanistic backdrop for our population-level findings, suggesting that both histological composition and anatomic context modulate SRCC behavior and therapeutic susceptibility. Despite the comprehensive analysis provided by this study, several limitations should be acknowledged. Firstly, as a retrospective study based on the SEER database, potential selection bias and unmeasured confounding factors may influence the results. In particular, a significant treatment selection bias is inherent, as patients who underwent surgery and/or CT likely represented a fitter subset with more favorable baseline performance status and fewer comorbidities, which could substantially confound the observed survival benefits. Secondly, the SEER database lacks information on recurrence patterns, molecular biomarkers (e.g., HER2 status, microsatellite instability [MSI], and other relevant molecular profiles), and specific treatment-related complications. The absence of these critical molecular data represents a notable limitation, as they are increasingly recognized as important prognostic and predictive factors that could confound survival outcomes and provide deeper insights into the biological behavior and therapeutic responses of advanced gastric and colorectal SRCC. Thirdly, the study period spans over two decades, during which advancements in diagnostic techniques, treatment protocols, and supportive care may have impacted survival outcomes, potentially introducing temporal bias. Lastly, the generalizability of our findings may be limited to populations with similar demographic and healthcare characteristics to those included in the SEER database. Future prospective studies incorporating detailed clinical and molecular data are warranted to validate these findings and further refine treatment strategies for advanced SRCC. In conclusion, this large population-based study highlights significant clinicopathological and prognostic differences between advanced gastric and colorectal SRCC, with colorectal SRCC demonstrating superior survival outcomes. Our findings suggest that the combination of surgery and CT is associated with the most favorable survival outcomes for both malignancies, underscoring the critical importance of multimodal therapy. Age, primary site, stage, treatment modality, and marital status were identified as independent prognostic factors, reflecting the complex interplay of clinical and social determinants in patient outcomes. Collectively, these results provide a compelling rationale for the development of standardized, site-specific treatment protocols tailored to the distinct biological behaviors of gastric and colorectal SRCC. Future research should focus on elucidating the molecular mechanisms underlying these disparities and exploring targeted therapies to further improve outcomes, particularly for gastric SRCC, where prognosis remains poor. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Determination of optimal age cut-off value. An X-tile plot analysis of age at diagnosis in the SEER cohort of advanced SRCC patients was used to determine the most statistically significant cut-off point for survival stratification, which was identified as 75 years. Supplementary Material 2 Supplementary Material 3 Acknowledgements None. Author contributions Jie Xu contributed to data collection and writing. Jie Xu and Luojie Liu were responsible for statistical analysis. Luojie Liu contributed to revising this dissertation. Zhaoji Zhu and Luojie Liu managed this project. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. Funding This study was supported by the Changshu Science and Technology Program (CY202339), the Suzhou Youth Science and Technology Project for the Advancement of Science, Education, and Health (KJXW2023067), and the Suzhou 23rd Batch of Science and Technology Development Plan (Clinical Trial Institution Capability Enhancement) Project (SLT 2023006). Data availability Publicly available datasets were analyzed in this study. These data can be accessed via the SEER Program database at the following link: https://seer.cancer.gov/. Additionally, detailed information regarding the datasets utilized in this research, including any preprocessing steps or supplementary metadata, is provided in the Supplementary File. Declarations Ethics approval and consent to participate Neither Institutional Review Board (IRB) approval nor explicit consent was required, given that the SEER database provides publicly accessible anonymized data. This study utilizes anonymized data from the SEER database. Patient information is anonymized to protect privacy, and consent for the use of their data in research is implied through the established protocols of the SEER program, in accordance with ethical standards and data use agreements. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Luojie Liu, Email: luojieliu@126.com. Zhaoji Zhu, Email: 675939591@qq.com. References Associated Data Supplementary Materials Supplementary Material 1. Determination of optimal age cut-off value. An X-tile plot analysis of age at diagnosis in the SEER cohort of advanced SRCC patients was used to determine the most statistically significant cut-off point for survival stratification, which was identified as 75 years. Supplementary Material 2 Supplementary Material 3 Data Availability Statement Publicly available datasets were analyzed in this study. These data can be accessed via the SEER Program database at the following link: https://seer.cancer.gov/. Additionally, detailed information regarding the datasets utilized in this research, including any preprocessing steps or supplementary metadata, is provided in the Supplementary File.